RNU6-267P

Across TCGA pan-cancer cohorts, RNU6-267P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNU6-267P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNU6-267P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-267P expression acts as an unfavorable survival marker, although some lineages such as ESCA and STAD show a favorable association.

CHOL, ESCA, and BRCA are the cancer types where RNU6-267P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.024	0.728	<.001	108	view →
ESCA	DFS	Tertile	II,III,IV	0.489	0.256	.003	51	view →
BRCA	OS	Tertile	IV	0.106	0.791	<.001	36	view →
LUAD	OS	Tertile	II,III,IV	0.422	0.761	.010	36	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	18	view →
UCEC	OS	Tertile	IV	0.308	0.748	.009	18	view →
STAD	OS	Tertile	II,III,IV	0.518	0.267	.018	17	view →
OV	DFS	Median	IV	0.354	0.506	.041	6	view →
MESO	DFS	Tertile	All	1.000	0.194	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RNU6-267P–CHOL (OS)

Open the CHOL breakdown →